Published in final edited form as:

Intern Med Rev (Wash D C). 2017 May ; 3(5): .

Lipid droplets, potential biomarker and metabolic target in glioblastoma

Feng Geng¹ and Deliang Guo¹

¹Department of Radiation Oncology, The Ohio State University James Comprehensive Cancer Center and College of Medicine, Columbus, OH 43210, USA

Abstract

Lipid droplets (LDs) are subcellular organelles that store large amounts of the neutral lipids, triglycerides (TG) and/or cholesteryl esters (CE). LDs are commonly formed in adipocytes, liver cells and macrophages, and their formation has been shown to be associated with the progression of metabolic diseases, i.e., obesity, fatty liver and atherosclerosis. Interestingly, LDs are also found in some tumor tissues. We recently showed that LDs are prevalent in glioblastoma (GBM), the most deadly brain tumor, but are not detectable in low-grade gliomas and normal brain tissues, suggesting that LDs may serve as a novel diagnostic biomarker for GBM. This short review will briefly introduce LD biology, summarize recent observations about LDs in several types of cancer tissues, and discuss LD formation in GBM. Moreover, we will highlight the role of SOAT1 (sterol-O transferase 1), a key enzyme regulating CE synthesis and LD formation in GBM, in the regulation of SREBP (sterol regulatory-element binding protein) activation. The therapeutic potential of LDs and SOAT1 will be discussed.

Introduction

Lipid droplets (LDs) are subcellular organelles that are the major storage site of neutral lipids, i.e., triglycerides (TG) and cholesteryl esters (CE), which form the lipid core that is surrounded by a monolayer of phospholipids (1-3). LDs have been found in most cells, from bacteria (4, 5), yeast (6, 7), and plant (8, 9) to mammals (10-12). Many terms have been used to refer to LDs, such as lipid bodies, adiposomes, spherosomes, oil bodies and fat bodies. Nevertheless, LDs have only begun to gain significant attention in the last few decades.

Cell biology of LDs

LDs are very small organelles found in many cells. The number and size of LDs vary significantly in different cell types, with a diameter usually around 1 μ m, but rarely larger than 10 μ m, although it can be >50 μ m in white adipocytes (11, 13). LDs are very dynamic organelles, and their number and size can change rapidly.

Correspondence: deliang.guo@osumc.edu, Tel: 614-366-3774, Fax: 614-247-1877.

Conflicting interests: The authors have declared that no competing interests exist.

LDs arise from the endoplasmic reticulum (ER), where the enzymes DGAT1 and DGAT2 (diacylglyceride acyltransferase) (14, 15), and SOAT1 and SOAT2 (sterol O-acyltransferase), also named ACAT1 and ACAT2 (acyl-coenzyme A:cholesterol acyltransferase) (16-20), convert excess cellular fatty acids and cholesterol to TG and CE in the interspace between the bilayer leaflets of the ER membrane (1, 2, 21). It has been hypothesized that the cytoplasmic leaflet of the ER membrane encloses the neutral lipids and buds from the ER into the cytoplasm to form LDs (22). Interestingly, several groups have reported that LDs are also observed in the cell nucleus (23-25), suggesting that LDs may have some function in the nucleus.

Hundreds of proteins have been found in purified LD fractions, although some of them may be included as a result of contamination due to the close association of LDs with other organelles including the ER, endosomes, peroxisomes and mitochondria (26, 27). Some proteins were identified as peripherally associated proteins and shown to regulate LD size and number, including the PAT-family of lipid droplet proteins, such as perilipin1, perilipin2 (ADRP), perilipin3 (Tip47), perilipin4, CIDE (Cell Death Inducing DNA Fragmentation Factor) proteins and several lipases (28-33). Perilipin1 is expressed primarily in adipose and steroidogenic cells (34), whereas perilipin2 and perilipin3 are ubiquitously expressed and serve as the predominant LD coat proteins in other tissues (35).

LDs and cancers

Deregulation of LD metabolism has been shown to correlate with various metabolic diseases including obesity, fatty liver, and atherosclerosis (1, 36-38). Interestingly, LDs are also observed in several types of tumor tissues from cancer patients (39-42). Accioly *et al.* found that LDs are present in biopsy samples from colon cancer patients (40). They reported that LDs were associated with the generation of prostaglandin E2 in colon adenocarcinoma cell lines. Yue *et al.* observed that CE and LDs are formed in high-grade human prostate cancer tissues, but not in normal prostate or benign prostatic tumor tissues (42). Guillaumond *et al.* reported that CE are present in pancreatic ductal adenocarcinoma (PDAC) tumors (43). Moreover, LDs were also observed in clear-cell renal cell carcinoma (ccRCC) patient samples. The study showed that overexpression of perilipin2 promoted lipid storage and tumor growth in ccRCC xenografts model (41). Nevertheless, while LDs are found in many cancers, their role in tumor pathophysiology has only started to be explored.

LDs and glioblastoma

Recent progress in the understanding of cancer biology has revealed that metabolism reprogramming is a new hallmark of malignancies (44-47). Our group was the first to report that lipid metabolism is rewired in glioblastoma (GBM) and promotes tumor growth (48-53). GBM is the most aggressive brain tumor and is also referred as grade IV astrocytoma. Despite extensive therapies, including surgical resection, radiation and chemotherapy, the median survival for GBM patients remains only 12-15 months from the initial diagnosis (54). The biggest challenge for treating GBM is the quickly developing resistance of tumor cells to therapies, leading to inevitable tumor recurrence and treatment failure (55, 56).

We recently uncovered that SREBP-1 (sterol regulatory element-binding protein-1), a master transcription factor in the regulation of lipid metabolism (57-59), is highly upregulated in GBM and promotes fatty acid synthesis (49, 51, 53, 60-62). Moreover, we found that GBM cells take up large amounts of cholesterol through LDLR (low-density lipoprotein receptor) that is also upregulated by SREBP-1 (63). It has been shown that significant increase in free fatty acids and cholesterol can cause ER stress and lipotoxicity that ultimately lead to cell death (41, 64-71). Interestingly, it is unclear how GBM cells are able to prevent the lipotoxicity potentially induced by the increased fatty acid synthesis and cholesterol uptake.

Most recently, using electron microscopy and fluorescence imaging, we observed that tumor tissues from GBM patients contain large amounts of LDs (72), suggesting that GBM cells may store excess fatty acids and cholesterol into LDs to prevent lipotoxicity and ER stress. Our data further showed that LDs are only present in GBM, and are not detectable in normal brain tissues and low-grade gliomas, demonstrating that LDs may serve as novel diagnostic biomarkers for GBM (72). Interestingly, when analyzing tumor tissues from a large cohort of GBM patients, we found that higher LD prevalence in tumor tissues was inversely correlated with overall survival (72), suggesting that LDs may play an important role in GBM growth.

SOAT1 and SREBPs

Our data showed that SOAT1 is highly expressed in GBM tumor tissues and that the levels of SOAT1 expression correlated with the prevalence of LDs (72). In contrast, SOAT2 was not detected in GBM (72), which is consistent with a previous report showing that SOAT2 is predominantly expressed in fetal liver and intestine tissues (17). Moreover, our data showed that genetic or pharmacologic inhibition of SOAT1 markedly reduced CE synthesis and LD formation in GBM cells, and suppressed GBM growth both *in vitro* and in orthotopic xenograft mouse models (72).

Interestingly, we further demonstrated that inhibition of SOAT1 significantly down-regulated SREBP activation and lipogenesis (72). SREBP activation is tightly regulated by ER cholesterol (57). Report shows that even an increase in ER cholesterol as low as 5% could significantly impede the trafficking of SREBP from the ER to the Golgi, leading to the reduction of SREBP-mediated lipogenesis (73, 74). Our data suggest that targeting SOAT1 to inhibit CE synthesis may cause the significant accumulation of cholesterol in the ER, leading to the suppression of SREBP activation (Figure. 1). It would be important to be able to measure ER cholesterol upon SOAT1 inhibition; unfortunately, we have not been successful, as we encountered difficulty to isolate pure ER fractions. Moreover, the cholesterol level in the ER is very low, corresponding to around 1-2% of total cellular cholesterol (75-77); thus, it is challenging to make accurate measurements for the changes in ER cholesterol with current fraction methodology.

The potential of SREBP being a molecular target in metabolic syndromes and cancer is supported by strong evidence (61, 78-80). Nevertheless, although SREBPs have been discovered around twenty years ago, the development of clinically effective inhibitors targeting SREBP has not been successful. Our study showing that restriction of SREBP in

the ER via enhancing ER cholesterol level through suppressing SOAT1 may be a promising strategy to treat metabolic syndromes and cancer (72). In fact, it has been shown that the SOAT inhibitor, avasimibe, which has already been tested in a Phase III clinical trial in atherosclerosis patients (81), significantly suppressed growth *in vitro* and *in vivo* in GBM and prostate cancer (72), 82, 83). Therefore, developing more effective inhibitors targeting SOAT1 may bring great hope for targeting GBM and other late-stage malignancies.

Future directions

Lately, LDs have attracted significant attention from researchers in the cancer field. The list of the different cancers containing LDs is quickly growing. Current evidence shows that LDs are mainly formed in the tumor tissues from patients at an advanced disease stage (42, 72). It would be worth examining the prevalence of LDs across cancer types and stages, which could provide important information about the correlation between LD formation and cancer progression. Moreover, there are many questions regarding the role of LDs in tumor tissues: 1) what are the underlying mechanisms regulating LD formation in tumor cells? 2) what is the exact role of LDs in cancer cells? 3) are LD formation and hydrolysis correlated with nutrient levels in cancer cells? 4) are LDs playing a role in tumor resistance to therapies? Undoubtedly, addressing these important questions will provide us great insights for understanding of cancer biology and metabolism reprogramming. Furthermore, investigating LD metabolism may identify promising metabolic targets and novel therapeutic approaches for cancer treatment.

Acknowledgments

This work was supported by the grants NIH NS079701 (DG), American Cancer Society Research Scholar Grant RSG-14-228-01-CSM (DG) and OSUCCC TT-seed grant (DG). The authors wish to thank colleagues who participated in the study of lipid droplets in glioblastoma, and thank Dr. Martine Torres for her critical reading of the manuscript and editorial help.

References

1. Walther TC, Farese RV Jr. The life of lipid droplets. *Biochim Biophys Acta*. 2009 Jun; 1791(6):459–66. [PubMed: 19041421]
2. Walther TC, Farese RV Jr. Lipid droplets and cellular lipid metabolism. *Annu Rev Biochem*. 2012; 81:687–714. [PubMed: 22524315]
3. Fei W, Shui G, Zhang Y, Krahmer N, Ferguson C, Kapterian TS, et al. A role for phosphatidic acid in the formation of “supersized” lipid droplets. *PLoS genetics*. 2011 Jul.7(7) e1002201.
4. Alvarez HM, Steinbuchel A. Triacylglycerols in prokaryotic microorganisms. *Appl Microbiol Biotechnol*. 2002 Dec; 60(4):367–76. [PubMed: 12466875]
5. Waltermann M, Hinz A, Robenek H, Troyer D, Reichelt R, Malkus U, et al. Mechanism of lipid-body formation in prokaryotes: how bacteria fatten up. *Mol Microbiol*. 2005 Feb; 55(3):750–63. [PubMed: 15661001]
6. Czabany T, Wagner A, Zweghtick D, Lohner K, Leitner E, Ingolic E, et al. Structural and biochemical properties of lipid particles from the yeast *Saccharomyces cerevisiae*. *J Biol Chem*. 2008 Jun; 283(25):20. 17065–74.
7. Athenstaedt K, Zweghtick D, Jandrositz A, Kohlwein SD, Daum G. Identification and characterization of major lipid particle proteins of the yeast *Saccharomyces cerevisiae*. *J Bacteriol*. 1999 Oct; 181(20):6441–8. [PubMed: 10515935]

8. Napier JA, Stobart AK, Shewry PR. The structure and biogenesis of plant oil bodies: the role of the ER membrane and the oleosin class of proteins. *Plant Mol Biol*. 1996 Aug; 31(5):945–56. [PubMed: 8843938]
9. Wanner G, Formanek H, Theimer RR. The ontogeny of lipid bodies (sphaerosomes) in plant cells : Ultrastructural evidence. *Planta*. 1981 Feb; 151(2):109–23. [PubMed: 24301718]
10. Szymanski KM, Binns D, Bartz R, Grishin NV, Li WP, Agarwal AK, et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. *Proc Natl Acad Sci U S A*. 2007 Dec; 104(52):26. 20890–5. [PubMed: 17182740]
11. Walther TC, Farese RV. Lipid Droplets and Cellular Lipid Metabolism. *Annual Review of Biochemistry*. 2012; 81:687–714.
12. Murphy DJ. The biogenesis and functions of lipid bodies in animals, plants and microorganisms. *Prog Lipid Res*. 2001 Sep; 40(5):325–438. [PubMed: 11470496]
13. Wang CW, Miao YH, Chang YS. Control of lipid droplet size in budding yeast requires the collaboration between Fld1 and Ldb16. *J Cell Sci*. 2014 Mar 15; 127(Pt 6):1214–28. [PubMed: 24434579]
14. Harris CA, Haas JT, Streeper RS, Stone SJ, Kumari M, Yang K, et al. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes. *Journal of lipid research*. 2011 Apr; 52(4):657–67. [PubMed: 21317108]
15. Karantonis HC, Nomikos T, Demopoulos CA. Triacylglycerol metabolism. *Curr Drug Targets*. 2009 Apr; 10(4):302–19. [PubMed: 19355855]
16. Sakashita N, Miyazaki A, Takeya M, Horiuchi S, Chang CC, Chang TY, et al. Localization of human acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues. *Am J Pathol*. 2000 Jan; 156(1):227–36. [PubMed: 10623671]
17. Chang CC, Sakashita N, Ornvold K, Lee O, Chang ET, Dong R, et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. *The Journal of biological chemistry*. 2000 Sep; 275(36):8. 28083–92.
18. Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. *Curr Opin Lipidol*. 2001 Jun; 12(3):289–96. [PubMed: 11353332]
19. Rogers MA, Liu J, Song BL, Li BL, Chang CC, Chang TY. Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): Enzymes with multiple sterols as substrates and as activators. *J Steroid Biochem Mol Biol*. 2014 Sep.:12.
20. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. *The Journal of biological chemistry*. 1998 Oct; 273(41):9. 26765–71. [PubMed: 9417037]
21. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. *Nature reviews Molecular cell biology*. 2006 May; 7(5):373–8. [PubMed: 16550215]
22. Wilfling F, Haas JT, Walther TC, Farese RV Jr. Lipid droplet biogenesis. *Curr Opin Cell Biol*. 2014 Aug; 29:39–45. [PubMed: 24736091]
23. Uzbekov R, Roingeard P. Nuclear lipid droplets identified by electron microscopy of serial sections. *BMC Res Notes*. 2013 Sep; 6:27. 386. [PubMed: 23343185]
24. Layerenza JP, Gonzalez P, Garcia de Bravo MM, Polo MP, Sisti MS, Ves-Losada A. Nuclear lipid droplets: a novel nuclear domain. *Biochim Biophys Acta*. 2013 Feb; 1831(2):327–40. [PubMed: 23098923]
25. Ohsaki Y, Kawai T, Yoshikawa Y, Cheng J, Jokitalo E, Fujimoto T. PML isoform II plays a critical role in nuclear lipid droplet formation. *J Cell Biol*. 2016 Jan; 212(1):04. 29–38.
26. Murphy S, Martin S, Parton RG. Lipid droplet-organelle interactions; sharing the fats. *Biochim Biophys Acta*. 2009 Jun; 1791(6):441–7. [PubMed: 18708159]
27. Krahmer N, Hilger M, Kory N, Wilfling F, Stoehr G, Mann M, et al. Protein correlation profiles identify lipid droplet proteins with high confidence. *Mol Cell Proteomics*. 2013 May; 12(5):1115–26. [PubMed: 23319140]
28. Kimmel AR, Brasaemle DL, McAndrews-Hill M, Sztalryd C, Londos C. Adoption of PERILIPIN as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins. *J Lipid Res*. 2010 Mar; 51(3):468–71. [PubMed: 19638644]

29. Yu J, Li P. The size matters: regulation of lipid storage by lipid droplet dynamics. *Sci China Life Sci.* 2017 Jan; 60(1):46–56. [PubMed: 27981432]
30. Xu W, Wu L, Yu M, Chen FJ, Arshad M, Xia X, et al. Differential Roles of Cell Death-inducing DNA Fragmentation Factor-alpha-like Effector (CIDE) Proteins in Promoting Lipid Droplet Fusion and Growth in Subpopulations of Hepatocytes. *J Biol Chem.* 2016 Feb; 291(9):26. 4282–93.
31. Wu L, Zhou L, Chen C, Gong J, Xu L, Ye J, et al. Cidea controls lipid droplet fusion and lipid storage in brown and white adipose tissue. *Sci China Life Sci.* 2014 Jan; 57(1):107–16. [PubMed: 24369348]
32. Sun Z, Gong J, Wu H, Xu W, Wu L, Xu D, et al. Perilipin1 promotes unilocular lipid droplet formation through the activation of Fsp27 in adipocytes. *Nat Commun.* 2013; 4:1594. [PubMed: 23481402]
33. Ye J, Li JZ, Liu Y, Li X, Yang T, Ma X, et al. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. *Cell Metab.* 2009 Feb; 9(2):177–90. [PubMed: 19187774]
34. Londos C, Brasaemle DL, Gruia-Gray J, Servetnick DA, Schultz CJ, Levin DM, et al. Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells. *Biochem Soc Trans.* 1995 Aug; 23(3):611–5. [PubMed: 8566427]
35. Brasaemle DL, Wolins NE. Packaging of fat: an evolving model of lipid droplet assembly and expansion. *J Biol Chem.* 2012 Jan; 287(4):20. 2273–9.
36. Farese RV Jr, Walther TC. Lipid droplets finally get a little R-E-S-P-E-C-T. *Cell.* 2009 Nov; 139(5):25. 855–60. [PubMed: 19804750]
37. Krahmer N, Guo Y, Farese RV Jr, Walther TC. SnapShot: Lipid Droplets. *Cell.* 2009 Nov 25; 139(5):1024–e1. [PubMed: 19945384]
38. Beckman M. Cell biology. Great balls of fat. *Science.* 2006 Mar; 311(5765):3. 1232–4.
39. Tosi MR, Tugnoli V. Cholesteryl esters in malignancy. *Clinica chimica acta; international journal of clinical chemistry.* 2005 Sep; 359(1-2):27–45. [PubMed: 15939411]
40. Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. *Cancer research.* 2008 Mar; 68(6):15. 1732–40.
41. Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, et al. HIF2alpha-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. *Cancer Discov.* 2015 Jun; 5(6):652–67. [PubMed: 25829424]
42. Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. *Cell metabolism.* 2014 Mar; 19(3):4. 393–406. [PubMed: 24411936]
43. Guillaumond F, Bidaut G, Ouaisi M, Servais S, Gouirand V, Olivares O, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. *Proc Natl Acad Sci U S A.* 2015 Feb; 112(8):24. 2473–8.
44. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science.* 2009 May; 324(5930):22. 1029–33. [PubMed: 19342557]
45. Masui K, Cavenee WK, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. *Brain Tumor Pathol.* 2016 Jul; 33(3):161–8. [PubMed: 27295313]
46. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. *Sci Adv.* 2016 May; 2(5) e1600200.
47. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. *Cell Metab.* 2016 Jan; 23(1):12. 27–47.
48. Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. *CNS Oncology.* 2013 May; 2(3):289–99. [PubMed: 24159371]
49. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. *Proceedings of the National Academy of Sciences of the United States of America.* 2009 Aug; 106(31):4. 12932–7. [PubMed: 19118193]

50. Ru P, Williams TM, Chakravarti A, Guo D. Tumor metabolism of malignant gliomas. *Cancers* (Basel). 2013; 5(4):1469–84. [PubMed: 24217114]
51. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. *Sci Signal*. 2009; 2(101):ra82.
52. Cheng C, Guo JY, Geng F, Wu X, Cheng X, Li Q, et al. Analysis of SCAP N-glycosylation and Trafficking in Human Cells. *J Vis Exp*. 2016 Nov 08.(117)
53. Cheng C, Ru P, Geng F, Liu J, Yoo JY, Wu X, et al. Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. *Cancer Cell*. 2015 Nov; 28(5):9. 569–81. [PubMed: 26175411]
54. Wen PY, Kesari S. Malignant gliomas in adults. *N Engl J Med*. 2008 Jul; 359(5):31. 492–507. [PubMed: 18596272]
55. Ricard D, Idhah A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. *Lancet*. 2012 May; 379(9830):26. 1984–96. [PubMed: 22225662]
56. Paleologos NA, Merrell RT. Anaplastic glioma. *Curr Treat Options Neurol*. 2012 Aug; 14(4):381–90. [PubMed: 22665140]
57. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell*. 2006 Jan; 124(1):13. 35–46. [PubMed: 16413474]
58. Nohturfft A, Zhang SC. Coordination of lipid metabolism in membrane biogenesis. *Annual review of cell and developmental biology*. 2009; 25:539–66.
59. Goldstein JL, Brown MSA. Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. *Cell*. 2015 Mar; 161(1):26. 161–72.
60. Guo D. SCAP links glucose to lipid metabolism in cancer cells. *Mol Cell Oncol*. 2016; 3(2)
61. Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. *Curr Pharm Des*. 2014; 20(15):2619–26. [PubMed: 23859617]
62. Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, et al. Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. *Cell Rep*. 2016 Aug; 16(6): 9. 1527–35. [PubMed: 27320911]
63. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, et al. An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. *Cancer Discov*. 2011 Sep; 1(5):15. 442–56.
64. Papazyan R, Sun Z, Kim YH, Titchenell PM, Hill DA, Lu W, et al. Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP. *Cell Metab*. 2016 Dec; 24(6):13. 863–74. [PubMed: 27411007]
65. Hager L, Li L, Pun H, Liu L, Hossain MA, Maguire GF, et al. Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice. *J Biol Chem*. 2012 Jun; 287(24):08. 20755–68.
66. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. *Endocrinology*. 2006 Jul; 147(7):3398–407. [PubMed: 16601139]
67. Lai E, Bikopoulos G, Wheeler MB, Rozakis-Adcock M, Volchuk A. Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. *Am J Physiol Endocrinol Metab*. 2008 Mar; 294(3):E540–50. [PubMed: 18198352]
68. Cao J, Dai DL, Yao L, Yu HH, Ning B, Zhang Q, et al. Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK/ATF4/CHOP signaling pathway. *Mol Cell Biochem*. 2012 May; 364(1-2):115–29. [PubMed: 22246806]
69. Zhang Y, Xue R, Zhang Z, Yang X, Shi H. Palmitic and linoleic acids induce ER stress and apoptosis in hepatoma cells. *Lipids Health Dis*. 2012 Jan.11:05. 1.
70. Kedi X, Ming Y, Yongping W, Yi Y, Xiaoxiang Z. Free cholesterol overloading induced smooth muscle cells death and activated both ER- and mitochondrial-dependent death pathway. *Atherosclerosis*. 2009 Nov; 207(1):123–30. [PubMed: 19467656]
71. Devries-Seimon T, Li Y, Yao PM, Stone E, Wang Y, Davis RJ, et al. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. *J Cell Biol*. 2005 Oct; 171(1):10. 61–73.

72. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, et al. Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis. *Clin Cancer Res*. 2016 Nov; 22(21):1. 5337–48.
73. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. *Cell Metab*. 2008 Dec; 8(6):512–21. [PubMed: 19041766]
74. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. *Proceedings of the National Academy of Sciences of the United States of America*. 2007 Apr; 104(16):17. 6511–8.
75. Holthuis JC, Menon AK. Lipid landscapes and pipelines in membrane homeostasis. *Nature*. 2014 Jun; 510(7503):4. 48–57.
76. Ikonen E. Cellular cholesterol trafficking and compartmentalization. *Nature reviews Molecular cell biology*. 2008 Feb; 9(2):125–38. [PubMed: 18216769]
77. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. *Nature reviews Molecular cell biology*. 2008 Feb; 9(2):112–24. [PubMed: 18216768]
78. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. *Cancer Metab*. 2013; 1(1):3. [PubMed: 24280005]
79. Li N, Zhou ZS, Shen Y, Xu J, Miao HH, Xiong Y, et al. Inhibition of the SREBP pathway suppresses hepatocellular carcinoma through repressing inflammation. *Hepatology*. 2016 Dec.;27.
80. Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. *Cell Metab*. 2011 Jan; 13(1):05. 44–56.
81. Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. *Circulation*. 2004 Nov; 110(21):23. 3372–7.
82. Lee SS, Li J, Tai JN, Ratliff TL, Park K, Cheng JX. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. *ACS Nano*. 2015 Mar; 9(3):24. 2420–32.
83. Li J, Gu D, Lee SS, Song B, Bandyopadhyay S, S Chen, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. *Oncogene*. 2016 Dec; 35(50):15. 6378–88.

Figure 1. SOAT1/ACAT1 regulates SREBP activation and GBM growth by promoting cholesterol esterification and LD formation

A) SOAT1/ACAT1 esterifies excess cellular cholesterol to form CE and LDs, thereby maintaining ER cholesterol homeostasis. This reduces the association of *N*-glycosylated SCAP (SREBP-cleavage activating protein) and Insig (insulin-induced gene protein), an ER-anchored protein, promoting SCAP/SREBP trafficking from the ER to the Golgi. In the Golgi, two proteases sequentially cleave SREBPs and release their N-terminal active forms, which then enter into the nucleus to activate lipogenesis gene expression for tumor growth (57, 72).

B) Inhibition of SOAT1/ACAT1 suppresses cholesterol esterification and LD formation, resulting in the accumulation of cholesterol in the ER. This enhances the binding of SCAP and Insig, thereby retaining the SCAP/SREBP complex in the ER, and leading to the reduction of lipogenesis and tumor suppression.

CE, cholesteryl esters; LDs, lipid droplets; ER, endoplasmic reticulum; SRE, sterol regulatory element; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; SCD1, stearoyl-CoA desaturase 1; HMGCR, HMG-CoA reductase.